| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug-Eluting Stents | 15 | 2019 | 562 | 3.10 | Why? |
| Coronary Artery Disease | 14 | 2021 | 2570 | 2.23 | Why? |
| Percutaneous Coronary Intervention | 25 | 2020 | 3646 | 1.88 | Why? |
| Fractional Flow Reserve, Myocardial | 6 | 2018 | 173 | 1.86 | Why? |
| Everolimus | 6 | 2018 | 215 | 1.68 | Why? |
| ST Elevation Myocardial Infarction | 18 | 2020 | 3051 | 1.63 | Why? |
| Coronary Stenosis | 5 | 2018 | 273 | 1.51 | Why? |
| Acute Coronary Syndrome | 12 | 2021 | 2107 | 1.41 | Why? |
| Coronary Circulation | 3 | 2019 | 188 | 1.34 | Why? |
| Platelet Aggregation Inhibitors | 9 | 2020 | 1671 | 1.28 | Why? |
| Coronary Angiography | 9 | 2021 | 2275 | 1.18 | Why? |
| Ticlopidine | 2 | 2017 | 193 | 1.07 | Why? |
| Absorbable Implants | 5 | 2019 | 191 | 1.04 | Why? |
| Coronary Vessels | 5 | 2021 | 914 | 0.97 | Why? |
| Cardiac Catheterization | 3 | 2018 | 882 | 0.95 | Why? |
| Receptors, Notch | 2 | 2019 | 59 | 0.86 | Why? |
| Myocardial Reperfusion | 2 | 2018 | 168 | 0.79 | Why? |
| Blood Platelets | 3 | 2020 | 1704 | 0.77 | Why? |
| Endothelium, Vascular | 4 | 2021 | 1751 | 0.77 | Why? |
| Peak Expiratory Flow Rate | 1 | 2017 | 64 | 0.70 | Why? |
| Catheterization | 1 | 2020 | 264 | 0.69 | Why? |
| Hand Strength | 1 | 2018 | 202 | 0.69 | Why? |
| Tricuspid Valve Insufficiency | 1 | 2018 | 94 | 0.66 | Why? |
| Cardiovascular Agents | 3 | 2018 | 663 | 0.65 | Why? |
| Physical Fitness | 1 | 2020 | 334 | 0.64 | Why? |
| Pulmonary Disease, Chronic Obstructive | 4 | 2017 | 3832 | 0.63 | Why? |
| Coronary Thrombosis | 5 | 2020 | 433 | 0.63 | Why? |
| Coronary Restenosis | 2 | 2017 | 153 | 0.61 | Why? |
| Prosthesis Failure | 1 | 2016 | 195 | 0.58 | Why? |
| Geriatric Assessment | 3 | 2020 | 1372 | 0.55 | Why? |
| Cardiovascular System | 2 | 2021 | 750 | 0.54 | Why? |
| Reactive Oxygen Species | 2 | 2017 | 1136 | 0.54 | Why? |
| Exercise Test | 2 | 2020 | 911 | 0.53 | Why? |
| Adenosine | 2 | 2017 | 509 | 0.53 | Why? |
| Heart Injuries | 1 | 2020 | 608 | 0.52 | Why? |
| Stents | 7 | 2020 | 916 | 0.52 | Why? |
| Platelet Activation | 1 | 2017 | 660 | 0.51 | Why? |
| Mitochondria | 2 | 2017 | 857 | 0.51 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.50 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.49 | Why? |
| Metals | 3 | 2019 | 182 | 0.47 | Why? |
| Hemorrhage | 4 | 2018 | 3013 | 0.45 | Why? |
| Myocardial Revascularization | 3 | 2018 | 267 | 0.45 | Why? |
| Lower Extremity | 1 | 2016 | 593 | 0.44 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.44 | Why? |
| Counseling | 1 | 2017 | 747 | 0.44 | Why? |
| Cause of Death | 5 | 2019 | 4823 | 0.41 | Why? |
| Propensity Score | 2 | 2018 | 2690 | 0.41 | Why? |
| Transcatheter Aortic Valve Replacement | 2 | 2018 | 839 | 0.40 | Why? |
| Peptide Fragments | 2 | 2018 | 2075 | 0.39 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.39 | Why? |
| Natriuretic Peptide, Brain | 1 | 2016 | 1215 | 0.39 | Why? |
| Mitochondrial Proton-Translocating ATPases | 2 | 2018 | 11 | 0.37 | Why? |
| Myocardium | 1 | 2020 | 2323 | 0.37 | Why? |
| Radial Artery | 3 | 2018 | 132 | 0.36 | Why? |
| Platelet Aggregation | 2 | 2020 | 318 | 0.36 | Why? |
| Frailty | 1 | 2020 | 1432 | 0.36 | Why? |
| Angioplasty, Balloon, Coronary | 3 | 2018 | 365 | 0.35 | Why? |
| Blood Flow Velocity | 2 | 2019 | 193 | 0.34 | Why? |
| Aspirin | 3 | 2019 | 1043 | 0.34 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.33 | Why? |
| Prosthesis Design | 6 | 2019 | 594 | 0.33 | Why? |
| Risk Assessment | 7 | 2020 | 25439 | 0.32 | Why? |
| Prospective Studies | 16 | 2021 | 43301 | 0.32 | Why? |
| Vascular Calcification | 2 | 2021 | 396 | 0.32 | Why? |
| Mitochondrial Membrane Transport Proteins | 3 | 2018 | 239 | 0.32 | Why? |
| Myocardial Reperfusion Injury | 2 | 2018 | 129 | 0.31 | Why? |
| Mortality | 3 | 2019 | 7132 | 0.31 | Why? |
| Treatment Outcome | 25 | 2021 | 51732 | 0.30 | Why? |
| Predictive Value of Tests | 6 | 2021 | 9537 | 0.28 | Why? |
| Aged | 40 | 2021 | 215776 | 0.27 | Why? |
| Aortic Valve | 3 | 2021 | 664 | 0.25 | Why? |
| Prognosis | 9 | 2021 | 32490 | 0.25 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2019 | 10649 | 0.25 | Why? |
| Myocardial Infarction | 7 | 2021 | 3361 | 0.25 | Why? |
| P-Selectin | 2 | 2021 | 224 | 0.24 | Why? |
| Survival Rate | 5 | 2019 | 9206 | 0.23 | Why? |
| Proof of Concept Study | 3 | 2019 | 696 | 0.22 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.22 | Why? |
| Humans | 67 | 2021 | 930598 | 0.22 | Why? |
| Male | 43 | 2021 | 367725 | 0.22 | Why? |
| Mitochondria, Heart | 2 | 2018 | 37 | 0.22 | Why? |
| CD40 Ligand | 1 | 2020 | 121 | 0.21 | Why? |
| Female | 42 | 2021 | 380317 | 0.21 | Why? |
| Pharmacogenomic Variants | 1 | 2020 | 112 | 0.20 | Why? |
| Postoperative Complications | 3 | 2018 | 5861 | 0.20 | Why? |
| Italy | 12 | 2021 | 38444 | 0.20 | Why? |
| Sirolimus | 2 | 2018 | 240 | 0.20 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.19 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.19 | Why? |
| Anticoagulants | 2 | 2018 | 9563 | 0.19 | Why? |
| Verapamil | 1 | 2018 | 46 | 0.18 | Why? |
| Sternotomy | 1 | 2018 | 45 | 0.18 | Why? |
| Thoracotomy | 1 | 2018 | 85 | 0.18 | Why? |
| Middle Aged | 31 | 2021 | 270681 | 0.18 | Why? |
| Hirudins | 1 | 2018 | 75 | 0.18 | Why? |
| Shear Strength | 1 | 2017 | 17 | 0.18 | Why? |
| Balloon Valvuloplasty | 1 | 2017 | 49 | 0.17 | Why? |
| Surgical Instruments | 1 | 2018 | 145 | 0.17 | Why? |
| Biomarkers | 5 | 2021 | 23361 | 0.17 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.17 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.17 | Why? |
| Coated Materials, Biocompatible | 1 | 2018 | 113 | 0.16 | Why? |
| Statistics, Nonparametric | 1 | 2020 | 1008 | 0.16 | Why? |
| Long Term Adverse Effects | 1 | 2017 | 119 | 0.16 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.16 | Why? |
| Electric Countershock | 1 | 2019 | 284 | 0.16 | Why? |
| Risk Factors | 16 | 2021 | 71621 | 0.15 | Why? |
| Clinical Decision-Making | 3 | 2019 | 3755 | 0.15 | Why? |
| Cardiotonic Agents | 1 | 2018 | 418 | 0.15 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 286 | 0.15 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.14 | Why? |
| Heart Valve Prosthesis Implantation | 2 | 2018 | 552 | 0.14 | Why? |
| Myocardial Ischemia | 2 | 2019 | 781 | 0.14 | Why? |
| Heparin | 2 | 2018 | 2600 | 0.14 | Why? |
| Thrombosis | 1 | 2017 | 7504 | 0.14 | Why? |
| Europe | 4 | 2020 | 12702 | 0.13 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.13 | Why? |
| Catheterization, Peripheral | 1 | 2017 | 249 | 0.13 | Why? |
| Platelet Count | 1 | 2019 | 1381 | 0.13 | Why? |
| Heart Valve Diseases | 1 | 2017 | 355 | 0.12 | Why? |
| Decision Support Techniques | 1 | 2020 | 903 | 0.12 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.12 | Why? |
| Heart Valve Prosthesis | 1 | 2018 | 533 | 0.12 | Why? |
| Bronchodilator Agents | 1 | 2017 | 444 | 0.12 | Why? |
| Signal Transduction | 3 | 2019 | 7207 | 0.12 | Why? |
| Cardiac Rehabilitation | 1 | 2018 | 525 | 0.11 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2017 | 490 | 0.11 | Why? |
| Recurrence | 5 | 2019 | 3675 | 0.11 | Why? |
| Coronary Artery Bypass | 1 | 2018 | 629 | 0.11 | Why? |
| Lung Injury | 1 | 2021 | 919 | 0.11 | Why? |
| Time Factors | 9 | 2021 | 31397 | 0.11 | Why? |
| Aged, 80 and over | 14 | 2021 | 88759 | 0.11 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.11 | Why? |
| Atherosclerosis | 1 | 2019 | 768 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.11 | Why? |
| Proteome | 1 | 2021 | 1812 | 0.11 | Why? |
| Computed Tomography Angiography | 1 | 2021 | 2153 | 0.11 | Why? |
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 869 | 0.10 | Why? |
| Myocytes, Cardiac | 1 | 2017 | 804 | 0.10 | Why? |
| Nitric Oxide | 1 | 2017 | 769 | 0.10 | Why? |
| Malnutrition | 1 | 2019 | 932 | 0.10 | Why? |
| Shock, Septic | 1 | 2019 | 1313 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.10 | Why? |
| Nutritional Status | 1 | 2019 | 1403 | 0.09 | Why? |
| Aorta, Thoracic | 2 | 2021 | 271 | 0.09 | Why? |
| Health Care Surveys | 1 | 2018 | 2942 | 0.09 | Why? |
| Stroke | 4 | 2021 | 8839 | 0.09 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.09 | Why? |
| Arrhythmias, Cardiac | 1 | 2021 | 2510 | 0.08 | Why? |
| Heart | 1 | 2017 | 1791 | 0.08 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Patient Selection | 2 | 2019 | 4560 | 0.08 | Why? |
| Home Care Services | 1 | 2018 | 1351 | 0.08 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.08 | Why? |
| Registries | 4 | 2021 | 12327 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2019 | 2040 | 0.07 | Why? |
| Odds Ratio | 1 | 2016 | 5861 | 0.07 | Why? |
| Spain | 2 | 2021 | 15545 | 0.07 | Why? |
| Patient Acceptance of Health Care | 2 | 2020 | 5002 | 0.07 | Why? |
| Atrial Fibrillation | 1 | 2019 | 2320 | 0.07 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.07 | Why? |
| Pilot Projects | 3 | 2021 | 5182 | 0.06 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.06 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.06 | Why? |
| Versicans | 1 | 2021 | 25 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| E-Selectin | 1 | 2021 | 55 | 0.06 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.06 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.05 | Why? |
| Structure-Activity Relationship | 2 | 2018 | 2219 | 0.05 | Why? |
| Mitogen-Activated Protein Kinases | 1 | 2021 | 126 | 0.05 | Why? |
| Vesicular Transport Proteins | 1 | 2021 | 110 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2021 | 189 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Heart Failure | 1 | 2021 | 6638 | 0.05 | Why? |
| Alkanes | 1 | 2018 | 4 | 0.05 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.05 | Why? |
| Mitochondria, Liver | 1 | 2018 | 18 | 0.05 | Why? |
| Antigens, Neoplasm | 1 | 2021 | 230 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.05 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2018 | 72 | 0.05 | Why? |
| Mitochondrial Membranes | 1 | 2017 | 12 | 0.04 | Why? |
| Global Health | 2 | 2019 | 13911 | 0.04 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.04 | Why? |
| Hematologic Agents | 1 | 2018 | 57 | 0.04 | Why? |
| Exercise | 1 | 2018 | 6771 | 0.04 | Why? |
| Animals | 5 | 2019 | 78931 | 0.04 | Why? |
| Recovery of Function | 2 | 2018 | 2461 | 0.04 | Why? |
| Angina Pectoris | 1 | 2018 | 114 | 0.04 | Why? |
| Self Expandable Metallic Stents | 1 | 2017 | 52 | 0.04 | Why? |
| Mobility Limitation | 1 | 2018 | 153 | 0.04 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2019 | 206 | 0.04 | Why? |
| Prasugrel Hydrochloride | 1 | 2017 | 114 | 0.04 | Why? |
| Rats, Wistar | 1 | 2018 | 621 | 0.04 | Why? |
| Permeability | 1 | 2017 | 238 | 0.04 | Why? |
| Intraoperative Care | 1 | 2018 | 238 | 0.04 | Why? |
| Biological Transport | 1 | 2017 | 290 | 0.04 | Why? |
| Aortic Diseases | 1 | 2021 | 362 | 0.04 | Why? |
| Protein Conformation | 2 | 2017 | 4386 | 0.04 | Why? |
| Calcium | 1 | 2021 | 708 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.04 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2021 | 243684 | 0.04 | Why? |
| Protein Subunits | 1 | 2018 | 755 | 0.04 | Why? |
| Femoral Artery | 1 | 2017 | 213 | 0.04 | Why? |
| Time | 1 | 2017 | 631 | 0.04 | Why? |
| Adenosine Triphosphate | 1 | 2017 | 294 | 0.03 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Single-Blind Method | 1 | 2018 | 1283 | 0.03 | Why? |
| Necrosis | 1 | 2017 | 532 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.03 | Why? |
| Electrocardiography | 2 | 2018 | 3957 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.03 | Why? |
| Exercise Tolerance | 1 | 2018 | 634 | 0.03 | Why? |
| Morbidity | 1 | 2019 | 1426 | 0.03 | Why? |
| Peripheral Arterial Disease | 1 | 2018 | 471 | 0.03 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.03 | Why? |
| Protein Multimerization | 1 | 2017 | 1336 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2017 | 1647 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 1047 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Small Molecule Libraries | 1 | 2018 | 1060 | 0.03 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.02 | Why? |
| Mice | 2 | 2018 | 21357 | 0.02 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2018 | 1962 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Brain Ischemia | 1 | 2020 | 2813 | 0.02 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Adult | 1 | 2017 | 244371 | 0.00 | Why? |